CRISPR QC, a San Diego-based biotechnology company that has developed the world’s first platform to precisely analyze the quality of the CRISPR/CAS9 gene editing system – has raised $10 million in funding led by Xcellerant Ventures.
By offering a way to standardize measurements for efficiency and accuracy, CRISPR QC enables pharmaceutical and agriculture companies to quickly screen for the best therapeutics to develop into next generation personalized medicines.
Xcellerant Ventures will help the company with strategic decisions as a board member. And as part of the investment, CRISPR QC opened an office in Scottsdale to utilize the growing expertise and talent in the semiconductor and medical device industries in Arizona.
KEY QUOTES:
“With CRISPR-based gene editing, we are at the beginning of a truly precise way to treat and cure thousands of genetically-driven diseases. We strongly believe CRISPR QC will be one of the required technologies for any company that wants to be in the business of developing personalized medicines.”
- Chris Yoo, Ph.D., GP of Xcellerant Ventures
“We have spoken with several venture funds who have strong interest in our technology, but we were looking for the ideal partner who could help us the most with our commercialization plans. It was instantly clear to us that Xcellerant Ventures was the investor and partner we have been searching for, and we are excited and honored to have Xcellerant lead our Series A.”
- Ross Bundy, CEO of CRISPR QC
